Novo Nordisk begins phase 1 trial for oral obesity drug LX9851

March 23, 2026 7:30 AM

Novo Nordisk A/S has initiated a Phase 1 clinical study for LX9851, an oral drug candidate for obesity treatment developed ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found